Drug Trial Radar · NCT06393738
A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
Last checked: Nov 20, 2026Latest source record: Sep 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
329
Planned (sponsor's estimate)
Start
Sep 5, 2024
Primary completion
Mar 2028
Study completion Mar 2028
Sponsor
- Lead sponsor
- Arvinas Inc.Industry
- Sponsor type
- Industry
- First posted
- May 1, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This clinical trial is studying the safety and potential anti-tumor activity of an investigational drug called ARV-393 in patients diagnosed with advanced Relapsed/Refractory non-Hodgkin's lymphoma (R/R NHL) to determine if ARV-393 may be a possible treatment option. ARV-393 is thought to work by breaking down a protein present in many types of non-Hodgkins lymphomas, which may prevent, slow or stop tumor growth. This is the first time ARV-393 will be used by people. The investigational drug will be given as an oral tablet.
Conditions
- Relapsed/Refractory (R/R) Mature B Cell Non Hodgkin Lymphoma (NHL)
- Relapsed/Refractory (R/R) Angioimmunoblastic T-cell Lymphoma (AITL)
Interventions
ARV-393Drug
Oral daily dose of ARV-393 at a specified dose level
GlofitamabDrug
Glofitamab infusion per labelled prescribing information
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Dose Limiting Toxicities During First 28 DaysTime frame: 28 days from first study dosing
- Percentage of Participants With Adverse Events Characterized by Severity, Seriousness, and Relationship to Study Drug as a Measure of Safety and TolerabilityTime frame: Parts A and B: From the study baseline to 30 days after last dose of ARV-393; Parts C and D: From the study baseline to 40 days after last dose of ARV-393
- Number of Participants With Abnormal Vital Signs, Abnormal ECG Readings (QT Interval) and Abnormal Laboratory ParametersTime frame: Parts A and B: From the study baseline to 30 days after last dose of ARV-393; Parts C and D: From the study baseline to 40 days after last dose of ARV-393
- Percentage of Participants With Grade 3 or Grade 4 Clinical Lab Abnormalities Using the Common Terminology Criteria for Adverse Events (CTCAE) With Scale From Grade 1 Grade 5. Higher Score Means Worse OutcomeTime frame: Parts A and B: From the study baseline to 30 days after last dose of ARV-393; Parts C and D: From the study baseline to 40 days after last dose of ARV-393
Locations
21 sites in 5 countries. Site status is shown where the registry gives one.
Clinical Trial Site
New Haven, Connecticut · Recruiting
Clinical Trial Site
Miami, Florida · Recruiting
Clinical Trial Site
Detroit, Michigan · Recruiting
Clinical Trial Site
New Brunswick, New Jersey · Recruiting
Clinical Trial Site
New York, New York · Recruiting
Clinical Trial Site
New York, New York · Recruiting
Clinical Trial Site
Cleveland, Ohio · Recruiting
Clinical Trial Site
Nashville, Tennessee · Withdrawn
Clinical Trial Site
Houston, Texas · Recruiting
Clinical Trial Site
Charlottesville, Virginia · Recruiting
Clinical Trial SIte
East Melbourne, Victoria, Australia · Recruiting
Clinical Trial SIte
Calgary, Alberta, Canada · Recruiting
Clinical Trial Site
Toronto, Ontario, Canada · Recruiting
Clinical Trial Site
Montreal, Quebec, Canada · Recruiting
Clinical Trial Site
Copenhagen, Denmark · Recruiting
Clinical Trial Site
Odense C, Denmark · Recruiting
Clinical Trial Site
Barcelona, Spain · Recruiting
Clinical Trial Site
Madrid, Spain · Recruiting
Clinical Trial Site
Salamanca, Spain · Recruiting
Clinical Trial Site
El Palmar, Murcia, Spain · Recruiting
Clinical Trial Site
Pamplona, Navarre, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.